Financial Analysis: Century Therapeutics Inc (IPSC)’s Ratios Unveil Key Insights

Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Century Therapeutics Inc’s stock clocked out at $1.21, down -2.42% from its previous closing price of $1.24. In other words, the price has decreased by -$2.42 from its previous closing price. On the day, 0.52 million shares were traded. IPSC stock price reached its highest trading level at $1.27 during the session, while it also had its lowest trading level at $1.2.

Ratios:

To gain a deeper understanding of IPSC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.39 and its Current Ratio is at 10.39. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.26.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on August 08, 2024, initiated with a Buy rating and assigned the stock a target price of $6.

On August 28, 2023, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $28 to $5.

On December 27, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $19.Chardan Capital Markets initiated its Buy rating on December 27, 2022, with a $19 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 04 ’24 when Farid Adrienne sold 1,033 shares for $1.23 per share. The transaction valued at 1,267 led to the insider holds 135,130 shares of the business.

Carr Douglas sold 283 shares of IPSC for $347 on Nov 04 ’24. The SVP Finance & Operations now owns 317,147 shares after completing the transaction at $1.23 per share. On Nov 04 ’24, another insider, Farid Adrienne, who serves as the Officer of the company, bought 1,033 shares for $1.23 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IPSC now has a Market Capitalization of 102885096 and an Enterprise Value of -40630860. For the stock, the TTM Price-to-Sale (P/S) ratio is 37.32 while its Price-to-Book (P/B) ratio in mrq is 0.52. Its current Enterprise Value per Revenue stands at -15.138 whereas that against EBITDA is 0.345.

Stock Price History:

Over the past 52 weeks, IPSC has reached a high of $5.51, while it has fallen to a 52-week low of $1.14. The 50-Day Moving Average of the stock is -16.90%, while the 200-Day Moving Average is calculated to be -54.38%.

Shares Statistics:

It appears that IPSC traded 385.54K shares on average per day over the past three months and 465860 shares per day over the past ten days. A total of 60.34M shares are outstanding, with a floating share count of 34.38M. Insiders hold about 59.56% of the company’s shares, while institutions hold 29.37% stake in the company. Shares short for IPSC as of 1730332800 were 3524985 with a Short Ratio of 9.14, compared to 1727654400 on 3492280. Therefore, it implies a Short% of Shares Outstanding of 3524985 and a Short% of Float of 5.09.

Most Popular